Washington Manual of Medical Therapeutics
Lipoglycopeptides
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
Treatment
Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA-approved for treatment of HABP and VABP caused by S. aureus and for complicated skin/soft tissue infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA, daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Treatment
Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA-approved for treatment of HABP and VABP caused by S. aureus and for complicated skin/soft tissue infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA, daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.
There's more to see -- the rest of this topic is available only to subscribers.
